Скачать или смотреть Do drugs get cheaper when their patents expire?

When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market. Lower prices are good news for patients seeking more affordable medications, but the change can sometimes take a while. Depending on the type of drug, the number of patents it has, and its placement on health insurance formularies, seeing a meaningful change in the list price of a drug can take anywhere from a few years to almost a decade.

The most well-known example of this process is AbbVie’s Humira, which was sheltered by dozens of patents from biosimilar competition for nearly seven years after its original patents expired. As a result, Humira was able to make billions of dollars off the biologic drug, which treats conditions such as rheumatoid arthritis and Crohn’s disease. 

This video shows how exactly AbbVie used patents to protect Humira, and explores how all the topics this series has covered so far — including generic drug entry mechanisms and pharmacy benefit managers — interact to influence the price of drugs. And if you need a refresher on biologics and biosimilars, it covers that, too.

STAT’s coverage of patent issues is supported by a grant from the Commonwealth Fund. Our financial supporters are not involved in any decisions about our journalism.

00:00 Intro
00:21 All drugs are not made equal
01:50 There's more than one patent
02:55 Patent thickets and terminal disclaimers
04:54 Pharmacy benefit managers are gatekeepers

More from STAT:

Become a subscriber: https://www.statnews.com/stat-plus/
Watch Full Episodes:    / @statnews  
Newsletters: https://www.statnews.com/signup/
STAT events: https://www.statnews.com/stat-events/
Facebook:   / statnews  
Twitter:   / statnews  
Instagram:   / statnews  
Flipboard: rb.gy/3xnsxr
STAT Reports: https://rb.gy/rexfwj
STAT eBooks: https://rb.gy/eme3h5

ABOUT STAT:
Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.